These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 18987649)

  • 21. ONTARGET proves telmisartan efficacy compared to ramipril in cardiovascular protection of patients at high risk and without heart failure.
    Cardiovasc J Afr; 2008; 19(2):108-9; discussion 109-10. PubMed ID: 18516357
    [No Abstract]   [Full Text] [Related]  

  • 22. The efficacy and safety of telmisartan compared to enalapril in patients with severe hypertension.
    Neutel JM; Smith DH; Reilly PA
    Int J Clin Pract; 1999; 53(3):175-8. PubMed ID: 10665127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of telmisartan and ramipril on adiponectin and blood pressure in patients with type 2 diabetes.
    Delles C; Raff U; Mimran A; Fauvel JP; Ruilope LM; Schmieder RE
    Am J Hypertens; 2008 Dec; 21(12):1330-6. PubMed ID: 18989258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension.
    Sengul AM; Altuntas Y; Kürklü A; Aydin L
    Diabetes Res Clin Pract; 2006 Feb; 71(2):210-9. PubMed ID: 16112244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor.
    Sleight P
    J Hypertens Suppl; 2009 Jul; 27(5):S23-9. PubMed ID: 19587551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry.
    Bramlage P; Schmieder RE; Gitt AK; Baumgart P; Mahfoud F; Buhck H; Ouarrak T; Ehmen M; Potthoff SA;
    Trials; 2015 Dec; 16():581. PubMed ID: 26686682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?
    Ong HT
    J Am Board Fam Med; 2009; 22(6):686-97. PubMed ID: 19897698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).
    Cowan BR; Young AA; Anderson C; Doughty RN; Krittayaphong R; Lonn E; Marwick TH; Reid CM; Sanderson JE; Schmieder RE; Teo K; Wadham AK; Worthley SG; Yu CM; Yusuf S; Jennings GL;
    Am J Cardiol; 2009 Dec; 104(11):1484-9. PubMed ID: 19932779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of circadian rhythms, posture, and medication on renin-aldosterone interrelations in essential hypertensives.
    Lamarre-Cliche M; de Champlain J; Lacourcière Y; Poirier L; Karas M; Larochelle P
    Am J Hypertens; 2005 Jan; 18(1):56-64. PubMed ID: 15691618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials.
    Lacourcière Y; Neutel JM; Schumacher H
    Clin Ther; 2005 Nov; 27(11):1795-805. PubMed ID: 16368450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of telmisartan on proteinuria or albuminuria: a meta-analysis of randomized trials.
    Takagi H; Yamamoto H; Iwata K; Goto SN; Umemoto T;
    Int J Cardiol; 2013 Aug; 167(4):1443-9. PubMed ID: 22560941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients.
    Petrovic I; Petrovic D; Vukovic N; Zivanovic B; Dragicevic J; Vasiljevic Z; Babic R
    J Int Med Res; 2005; 33 Suppl 1():39A-49A. PubMed ID: 16222899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy of telmisartan compared with perindopril in patients with mild-to-moderate hypertension.
    Nalbantgil I; Nalbantgil S; Ozerkan F; Yilmaz H; Gürgün C; Zoghi M; Aytimur M; Onder R
    Int J Clin Pract Suppl; 2004 Dec; (145):50-4. PubMed ID: 15617460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective, randomized, single-blind comparison of effects of 6 months of treatment with telmisartan versus enalapril on high-molecular-weight adiponectin concentrations in patients with coronary artery disease.
    Satoh M; Tabuchi T; Minami Y; Takahashi Y; Itoh T; Nakamura M
    Clin Ther; 2009 Oct; 31(10):2113-25. PubMed ID: 19922882
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension.
    Nedogoda SV; Ledyaeva AA; Chumachok EV; Tsoma VV; Mazina G; Salasyuk AS; Barykina IN
    Clin Drug Investig; 2013 Aug; 33(8):553-61. PubMed ID: 23800977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?
    Cohn JN
    Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):526-7. PubMed ID: 18665135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study.
    Barnett AH
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S42-9. PubMed ID: 15868119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Achieving blood pressure goals: should angiotensin II receptor blockers become first-line treatment in hypertension?
    Weber M
    J Hypertens Suppl; 2009 Jul; 27(5):S9-14. PubMed ID: 19587555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
    Tobe SW; Clase CM; Gao P; McQueen M; Grosshennig A; Wang X; Teo KK; Yusuf S; Mann JF;
    Circulation; 2011 Mar; 123(10):1098-107. PubMed ID: 21357827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypertension treatment and implications of recent cardiovascular outcome trials.
    Weber MA
    J Hypertens Suppl; 2006 Apr; 24(2):S37-44. PubMed ID: 16601560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.